

Title Ophthalmology High Cost Drugs

Reference Number: RDF1541-23

Date of Response: 21/06/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition*:

	Trust Total
Aflibercept	1,982
Bevacizumab	33
Brolucizumab	*<5
Dexamethasone	74
Faricimab	64
Ranibizumab	202

[*] Eye condition defined as any contact on the patient database presenting with condition diagnosed to Chapter VII of the ICD-10 index:
Diseases of the eye and adnexa (H00-H59)

[**] We cannot conclusively say these patients were treated for a specific diagnoses, just that they have been prescribed one of the drugs listed between January and April 2023 and also have a primary or secondary diagnoses relating to Chapter VII "Diseases of the eye and adnexa"

Section 40 (2) - *<5

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients/staff is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. †

	East*
Aflibercept	196
Bevacizumab	0
Brolucizumab	N/A
Dexamethasone	12
Faricimab	0
Ranibizumab	5

[*] Includes any patient previously administered one of the anti-VEGF therapies listed since October 2020

[†] In order to distinguish which of the Northern patient cohort were new to anti-VEGF therapy, access to pre-EPIC pharmacy data is required. BI does not have access to these legacy systems. It is therefore only possible for us to provide answers from an Eastern **perspective**.